['neovascular age-related macular degeneration', 'choroidal neovascularization']
['brolucizumab ophthalmic solution', 'aflibercept ophthalmic solution']

        Key Inclusion Criteria:

          -  Provide written informed consent;

          -  Active CNV lesions secondary to AMD that affected the central subfield in the study
             eye at Screening;

          -  Total area of CNV > 50% of the total lesion area in the study eye at Screening;

          -  Intraretinal and/or subretinal fluid affecting the central subfield of the study eye
             at Screening;

          -  Best corrected visual acuity (BCVA) between 78 and 23 letters, inclusive, in the study
             eye at Screening and Baseline using Early Treatment Diabetic Retinopathy Study (ETDRS)
             testing.

        Key Exclusion Criteria:

          -  Any active intraocular or periocular infection or active intraocular inflammation in
             either eye at Baseline;

          -  Central subfield of the study eye affected by fibrosis or geographic atrophy or total
             area of fibrosis ≥ 50% of the total lesion in the study eye at Screening;

          -  Subretinal blood affecting the foveal center point and/or ≥ 50% of the lesion of the
             study eye at Screening;

          -  Any approved or investigational treatment for neovascular age-related macular
             degeneration (nAMD) in the study eye at any time;

          -  Retinal pigment epithelial rip/tear in the study eye at Screening or Baseline or
             current vitreous hemorrhage or history of vitreous hemorrhage in the study eye within
             4 weeks prior to Baseline;

          -  Pregnant or nursing women; women of child-bearing potential;

          -  Stroke or myocardial infarction in the 6-month period prior to Baseline.
      